Clinical trial
Rebeccamycin Analog in Treating Children With Relapsed or Refractory…
NCT00003737 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00003737 |
|---|---|
| Title | Rebeccamycin Analog in Treating Children With Relapsed or Refractory Neuroblastoma |
| Official title | A Pharmacokinetic-Guided Phase II Trial of the Rebeccamycin Analog NSC# 655649 in Pediatric Patients With Relapsed/Refractory Neuroblastoma |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neuroblastoma |
| Intervention type | Drug |
| Interventions | becatecarin |
| Enrollment | 30 |
| Start date | Jan 1, 1999 |
| Primary completion | Sep 1, 2006 |
| Completion | Sep 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 25, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: